Regeneron Pharmaceuticals

What the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.

• Identityunclaimed
  Published
• Evidencesource_reported
  Published
• Evaluationnot_evaluated
  Published
• MonitoringNot yet published for this record.
  Not published
• AuthorityNot yet published for this record.
  Not published
• Freshnesscurrent
  Published

13 directors published. 11 of 13 with a published determination are independent.

Who can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.

Published Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.

A gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.

• Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
• OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
• FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
• CompensationNot reviewed. Pay design shows how incentives are governed.
• GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
• Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
• AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
• LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
• RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
• CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
• AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
• Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
• Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
• Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
• Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
• This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.

• LS
  Leonard S. SchleiferChief Executive Officer; Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:26, company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:19
• AJ
  Andrew J. Murphy, Ph.D.Executive Vice President, Co-Chief Scientific Officer
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:22
• CF
  Christopher FenimoreExecutive Vice President, Finance and Chief Financial Officer
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:23
• DP
  Daniel P. Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:24
• GD
  George D. Yancopoulos, M.D., Ph.D.Board co-Chair, President and Chief Scientific Officer
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:25
• LS
  Leonard S. Schleifer, M.D., Ph.D.Board co-Chair, President and Chief Executive Officer
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:27
• AJ
  Anita J. RyanIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:9
• BL
  Bonnie L. BasslerIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:10
• CA
  Christine A. PoonLead Independent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:11
• CB
  Craig B. ThompsonDirector
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:12
• DP
  David P. SchenkeinIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:13
• GD
  George D. YancopoulosDirector
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:14
• GL
  George L. SingIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:15
• HY
  Huda Y. ZoghbiIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:16
• JL
  Joseph L. GoldsteinIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:17
• KG
  Kathryn GuariniIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:18
• MS
  Michael S. BrownIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:20
• NA
  N. Anthony ColesIndependent Director
  company:bee12477-9858-4107-8779-4e9347bf356a:leadership_role:21

This record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.

Basis

Published company record built from public sources

Sources

8 evidence records cited. 0 with redistribution rights.

Never published

Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry

Record claimed

No

Open disputes

0

Identity ownership

unclaimed

If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.

1. E1
   Alpha canonical company public projection

   Alpha canonical company public projection. canonical identity. Retrieved Oct 16, 2026. Cited by 6 Claims.
   Open web
   Rights not recorded, link only
   Evidence not pinned
2. E2
   REGENERON PHARMACEUTICALS, INC. Form 10-K (filed 2026-02-04)

   REGENERON PHARMACEUTICALS, INC. Form 10-K (filed 2026-02-04). SEC filing. Retrieved Aug 29, 2026. Cited by 2 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
3. E3
   Regeneron Pharmaceuticals, Inc. DEF 14A 2026-04-24

   sec proxy. Published Apr 24, 2026. Retrieved Apr 24, 2026. Cited by 13 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
4. E4
   SEC DEF 14A 0001308179-26-000340

   sec def 14a. Published Apr 24, 2026. Retrieved Sep 14, 2026. Cited by 5 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
5. E5
   REGN 10-K executive officers

   sec filing. Published Feb 4, 2026. Retrieved Jul 11, 2026. Cited by 1 Claim.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
6. E6
   Audit

   board_seats. sp500-board-director-completeness-remediation-2026-05-15. Cited by 14 Claims.
   Authoritative, regulatory filing
   Rights not recorded, link only
   Evidence not pinned
7. E7
   S&P 500

   Slickcharts S&P 500 constituent table (public observation, not S&P DJI license). index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
   Open web
   Rights not recorded, link only
   Evidence not pinned
8. E8
   Nasdaq-100

   Nasdaq official Nasdaq-100 list-type API. index provider. Retrieved Sep 2, 2026. Cited by 1 Claim.
   Open web
   Rights not recorded, link only
   Evidence not pinned

• Leonard S. Schleifer executive of Regeneron Pharmaceuticals, effective 2026-02-04.
• David P. Schenkein seat on Regeneron Pharmaceuticals, effective 2023-01-01.
• Kathryn Guarini seat on Regeneron Pharmaceuticals, effective 2023-01-01.
• Craig B. Thompson seat on Regeneron Pharmaceuticals, effective 2022-01-01.
• Corporate Governance and Compliance; Digital Technology; Technology committee of Regeneron Pharmaceuticals, effective 2022-01-01.
• Craig B. Thompson member of Corporate Governance and Compliance; Digital Technology; Technology, effective 2022-01-01.
• N. Anthony Coles seat on Regeneron Pharmaceuticals, effective 2017-01-01.
• Bonnie L. Bassler seat on Regeneron Pharmaceuticals, effective 2016-01-01.
• Huda Y. Zoghbi seat on Regeneron Pharmaceuticals, effective 2016-01-01.
• Christine A. Poon seat on Regeneron Pharmaceuticals, effective 2010-01-01.
• Christine A. Poon lead independent director of Regeneron Pharmaceuticals, effective 2010-01-01.
• Compensation · Chair; Corporate Governance and Compliance committee of Regeneron Pharmaceuticals, effective 2010-01-01.
• Christine A. Poon member of Compensation · Chair; Corporate Governance and Compliance, effective 2010-01-01.
• Anita J. Ryan seat on Regeneron Pharmaceuticals, effective 2003-01-01.
• Audit; Corporate Governance and Compliance · Chair committee of Regeneron Pharmaceuticals, effective 2003-01-01.
• Anita J. Ryan member of Audit; Corporate Governance and Compliance · Chair, effective 2003-01-01.
• George D. Yancopoulos seat on Regeneron Pharmaceuticals, effective 2001-01-01.
• Joseph L. Goldstein seat on Regeneron Pharmaceuticals, effective 1991-01-01.
• Michael S. Brown seat on Regeneron Pharmaceuticals, effective 1991-01-01.
• George L. Sing seat on Regeneron Pharmaceuticals, effective 1988-01-01.
• Leonard S. Schleifer seat on Regeneron Pharmaceuticals, effective 1988-01-01.
• Audit · Chair; Compensation committee of Regeneron Pharmaceuticals, effective 1988-01-01.
• George L. Sing member of Audit · Chair; Compensation, effective 1988-01-01.